The ILÚM technology analyzes patient data in accordance with institution-specific guidelines and highlights high-risk patients and intervention opportunities, decreasing cognitive load on the care team.
Notifications from ILÚM are routed in real-time to the assigned caregiver or on-call AMS team, enabling immediate triage and rapid coordination between the care team and pharmacy for medication changes all in one smartphone application.
PatientSafe Solutions delivers measurable safety and quality improvements through a mobile platform that extends an organization's EHR, clinical, and communication infrastructure.
The company's context-driven PatientTouch platform unifies communication with workflow by consolidating text, talk, alerts, EMR data, clinical workflows and customizable care interventions in one mobile app, on one device.
ILÚM Health Solutions provides technology and services to support infectious disease management. ILÚM is part of Healthcare Services and Solutions, LLC, an independent business unit focused on improving the value of care delivered to patients through evidence-based services and solutions.
Poolbeg PHarma plc receives notice of allowance for POLB 001 patent
RedHill Biopharma secures USPTO Patent for Talicia, extending protection through 2034
Micron Biomedical names new scientific advisor to CEO
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial